Install
The Manila Times is a national daily newspaper in the Philippines that delivers trusted, quality content in print and digital editions.
- 6,558articles · 30d
- 2+ hour agolatest article
- Aug 14, 2026earliest in window
- 92%with images
- 271avg words
- Economy, Business & Finance 3,071
- Finance & Business 2,386
- News 2,022
- Business & Industrial 795
- Politics 657
- Finance 564
- Science & Technology 448
- Arts, Culture, Entertainment & Media 440
Please confirm you are human
This browser or connection looks automated. Press and continuously hold the control for 3 seconds to enable Google-hosted web results and, when separately allowed, AI-assisted answers.
A successful check enables 100 search requests. Interactive access does not authorize scraping, systematic collection, or reuse of search output.
News
Never Fight Alone Turns Five: Crisis Text Line and Gears of War Reinforce Commitment to Suicide Prevention
3+ day, 2+ hour ago (112+ words) Milestone partnership has supported more than 16,000 conversations with people in mental health crisis since 2021 This will be Gears of War’s fifth year donating 1% of all net revenue from its games and merchandise to Crisis Text Line. Over the past five…...
Harbour BioMed Partner, Solstice Oncology, announces $225 Million Series A Financing to Advance Porustobart, a Neoadjuvant Immuno-Oncology Therapy
4+ day, 5+ hour ago (682+ words) **media[1209302]**Porustobart, a second-generation Fc-enhanced CTLA-4 antibody, is being advanced across two clinical indications in the neoadjuvant setting, beginning with MSS clinical stage II-III colon cancerPhase 2 trial of porustobart for colon cancer will be open for enrollment early in the…...
OKYO Pharma to Present at Ophthalmology Futures European Forum and iNovation Day at ESCRS 2026
4+ day, 5+ hour ago (190+ words) Company to engage with the global ophthalmology and investment community as it advances urcosimod through its global Phase 3 pivotal trial for neuropathic corneal pain LONDON and NEW YORK, Sept. 09, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company…...
ViaNautis Bio welcomes SCI Ventures as new investor, expanding CNS portfolio into spinal cord injury
4+ day, 8+ hour ago (468+ words) Investment supports application of ViaNautis’ polyNaut® platform to regenerative therapies for spinal cord injury, where targeted delivery remains a huge barrierAdds a new high-value CNS indication and provides further validation of polyNaut® as a versatile platform for precise, non-viral delivery…...
Allegro’s Hydrocelin significantly improves knee osteoarthritis pain and function in clinical trial
4+ day, 9+ hour ago (152+ words) Hydrocelin is a first-in-class nanotechnology designed to restore the shock-absorbing properties of the joint. Unlike conventional injectable products, which primarily provide lubrication or temporary symptom relief, Hydrocelin has been developed to address the loss of the joint's natural protective mechanics,…...
‘Secondhand smoke causes 1.7M deaths’
5+ day, 25+ min ago (279+ words) Tobacco remains a leading cause of disease globally, the study said, noting many “non-smokers exposed to secondhand smoke” were among the estimated total of 8 million people who died in 2023 of smoking-related illnesses. “Exposure to secondhand smoke is a globally recognized…...
Monte Rosa Therapeutics Announces Milestone Achievement Associated with Initiation of Phase 2 Clinical Study for VAV1-directed Molecular Glue Degrader MRT-6160 (DDY391)
5+ day, 5+ hour ago (723+ words) The Manila Times Monte Rosa Therapeutics Announces Milestone Achievement Associated with Initiation of Phase 2 Clinical Study for VAV1-directed Molecular Glue Degrader MRT-6160 (DDY391) Phase 2 study to be conducted in participants with Sjögren’s disease Novartis conducting study under global exclusive development and…...
PannTheraPi Receives ANSM Approval to Advance PTI5803 into Phase 2a in Focal Cortical Dysplasia
5+ day, 9+ hour ago (133+ words) Phase 2a study to evaluate PannTheraPi’s first-in-class Pannexin 1-targeting therapy in patients with drug-resistant FCD, a rare and severe form of epilepsy PTI5803 is an oral small molecule targeting the Panx1 channel and is being developed as a potential first-in-class treatment for FCD,…...
Greywolf Therapeutics doses first participants with axSpA in novel ERAP1 inhibitor trial
5+ day, 10+ hour ago (302+ words) GRWD0715, a first-in-class oral ERAP1 inhibitor to treat CD8+ T cell-mediated autoimmunity, has now been dosed in participants with axSpA after the completion of the SAD portion of its Phase 1/2 study (EAST-1) in healthy volunteers, demonstrating dose-proportional PK, clear evidence of ERAP1 target engagement,…...
Shooting victim needs more funds for surgery
6+ day, 40+ min ago (251+ words) TACLOBAN CITY — The family of Joan Vinias, one of the survivors of the San Jose National High School shooting, is seeking assistance as the young survivor prepares to undergo surgery on Sept. 10. Joan is scheduled to undergo a cranioplasty at…...